

## Ziphilus Announces Appointment of Damien Dessis as Chief Business Officer (CBO)

Ghent, Belgium and New York, US; 10 October 2024

Ziphilus, a leading biotechnology company developing self-amplifying RNA (saRNA) vaccines and therapeutics, today announced the appointment of Damien Dessis as Chief Business Officer. In this role, Mr. Dessis will be responsible for overseeing the Company's business development and overall corporate strategy.

### Mr. Damien Dessis

Mr. Dessis is an experienced biotech executive with over 20 years in the vaccines and pharmaceutical industries. Most recently Mr. Dessis served as VP of Business & Corporate Development at Valneva, overseeing vaccine R&D and commercial stage deals and alliances. He also advised and held senior roles in various biotech companies, tech transfer offices and academic research centers, focusing on strategy, global business expansion and partnerships. Mr. Dessis started his career at GlaxoSmithKline Vaccines, where he led early-stage product strategy, business development & licensing initiatives and pandemic response activities.

Mr. Dessis holds a DESS in International Industrial Project Management from the University of Strasbourg, a Master's in Innovation in Biology from Polytech Angers, and completed executive programs at Harvard Business School and INSEAD.

*"I'm excited to bring my expertise in biotech strategy, business development and strategic partnerships to Ziphilus. I look forward to working with the talented team at Ziphilus to advance its innovations in vaccines and therapeutics technology and drive change in the healthcare sector," said Damien Dessis.*

**Chris Cardon, CEO of Ziphilus, continued:** *"We are excited to welcome Damien to the Ziphilus team. His extensive experience in business development will be crucial as we continue to develop and expand our proprietary saRNA and carrier technology (LNP) platforms."*

### About Ziphilus

Ziphilus is a biotechnology company developing best-in-class vaccines and therapeutics based on its proprietary saRNA and carrier technology (LNP) platform to allow for a higher and prolonged protein/antigen expression at lower doses compared to conventional mRNA with reduced toxicity. This platform has the potential for a 'plug and play' approach offering the possibility of fast development/scale-up and production. These attributes make it well suited as platform to improve pandemic preparedness. Based in Ghent (Belgium) and New York (US) the companies present pipeline showcases strategic developments in infectious diseases and protein replacement therapies.

For more information, visit [www.ziphilus.org](http://www.ziphilus.org), and follow us on [LinkedIn](#).